Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
This exercise of the buy-out option will contribute to reinforcing the drug discovery and research platform for biologics as well as enriching pipeline in…
MAXY-4 was positioned as offering 'an improved therapeutic profile' vs BMS's Orencia and belatacept, and the buyout signals Astellas's confidence in the…
Astellas has completed its purchase of all of Maxygen's equity interests in Perseid Therapeutics LLC for $76.0 million in cash.
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Astellas exercised its option to acquire Maxygen's stake in JV Perseid Therapeutics for $76M, taking full control of the protein-engineering platform and pipeline candidates. Below the typical $250M threshold but strategically notable for protein engineering consolidation.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Astellas Pharma Inc. / Maxygen, Inc. (Perseid Therapeutics stake) (this deal) | 2011 | $76M | 11 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
| Astellas Pharma Inc. / Ganymed Pharmaceuticals | 2016 | $1.4B | 81 |
| Astellas Pharma Inc. / Sangamo Therapeutics, Inc. | 2026 | $50M | 63 |
| Astellas Pharma Inc. / Ogeda SA | 2017 | $850M | 59 |
| Astellas Pharma Inc. / Ocata Therapeutics, Inc. | 2015 | $379M | 41 |
| Astellas Pharma Inc. / Optimer Pharmaceuticals, Inc. | 2012 | $90M | 38 |
← Browse all deals · How we score deals
More: 2011 deals · Astellas Pharma Inc. deals · Immunology deals